FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula Ib, where R1 denotes -OMe, -OEt or -CN; R4 independently denotes -NRC(O)R or -N(R)2; R5 denotes methyl; each R is independently hydrogen, C1-4 alkyl, optionally substituted with 4-methylpiperazinyl, 1-methylpiperidinyl or -OH; r denotes 1 and t denotes 1, or their tautomers or stereoisomers and/or pharmaceutically acceptable salts, as antagonists of toll-like receptors 7/8 (TLR7/8).
EFFECT: disclosed are pharmaceutical compositions containing them for inhibiting TLR7/8 activity, a method of inhibiting TLR7/8 activity and a method of treating a TLR7/8 mediated disorder in a patient, wherein the disorder is selected from lupus, polymyositis, dermatomyositis, Sjogren's syndrome and rheumatoid arthritis.
11 cl, 1 tbl, 391 ex.
| Title | Year | Author | Number |
|---|---|---|---|
| TLR7/8 ANTAGONISTS AND THEIR APPLICATION | 2017 |
|
RU2758686C2 |
| POLYCYCLIC ANTAGONISTS OF TLR7/8 AND THEIR USE IN TREATMENT OF IMMUNE DISORDERS | 2016 |
|
RU2783748C2 |
| SPLICEOSTATIN ANALOGS | 2013 |
|
RU2618523C2 |
| CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
| SECONDARY MANNOSIS FOR BACTERIAL INFECTIONS TREATMENT | 2013 |
|
RU2667060C2 |
| ISOINDOLINONE INHIBITORS OF MDM2-P53 INTERACTION WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2797295C1 |
| INHIBITORS OF METALLOPROTEINASES, THEIR USING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2002 |
|
RU2288228C2 |
| DERIVATIVE 6-CARBONITRILE DIPYRIDOPYRROLES AND APPLICATION THEREOF IN CANCER TREATMENT | 2010 |
|
RU2575635C2 |
| REGULATORS-DERIVATIVES OF STEROIDS, METHODS OF THEIR OBTAINING AND THEIR USE | 2019 |
|
RU2797408C2 |
| C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | 2011 |
|
RU2606501C2 |
